Management Team & Directors

Dr. Francis E. O'Donnell, Jr., Executive Chairman


Frank E. O’Donnell, Jr., M.D. is our Executive Chairman of the Board and a Director of our company. He served as the Executive Chairman of the Board of Directors of Hedgepath Pharmaceuticals, Inc. from 2013-2016, and served as the Chairman of the Board of BioDelivery Sciences International (NASDAQ:BDSI) from March 2002 through 2018. Dr. O’Donnell has been involved with various private limited liability companies which engage in private equity and venture capital investing in disruptive technologies in healthcare. Dr. O’Donnell is a graduate of The Johns Hopkins School of Medicine and received his residency training at the Wilmer Ophthalmological Institute, Johns Hopkins Hospital. Dr. O’Donnell is a former professor and Chairman of the Department of Ophthalmology, St. Louis University School of Medicine. He is a trustee of St. Louis University.

Dr. Barry I. Feinberg, President and CEO, Director


Dr. Barry I. Feinberg has been our President and Chief Executive officer since July 2017 and has served as a member of our board since December 23, 2014. He has also a member of the Board of Directors for BioDelivery Sciences, International. Dr. Feinberg is an expert in the area of pain management and has served as adjunct faculty member of the Department of Anesthesia at Saint Louis University since November 2013. Since 2006, he has also served as a member of the Board of Directors and Medical Executive Committee of the Frontenac Surgery and Spine Care Center, where he maintains his private practice under the name Injury Specialists. From 2003 to 2011, Dr. Feinberg served as a member of the Board of Directors of Professional Imaging, LLC. He has served as a staff member of the Department of Anesthesia at the Missouri Baptist Medical Center in St. Louis, Missouri since August 2004 and as an associated staff member of the Department of Anesthesia at the DePaul Health Center in Bridgeton, Missouri, since June 1995. From 1988 to 1994, Dr. Feinberg served as Director of the Physicians' Pain Management Center in Bridgeton, Missouri, and the Chairman of the Department of Anesthesia at DePaul Heath Center in Bridgeton from 1986 to 1994. He has also served as Assistant Professor at the Department of Anesthesia at Mount Sinai Medical Center from 1984 to 1986 and staff member at the Intensive Care Unit of the Deborah Heart and Lung Center in Browns Mill, New Jersey, from 1983 to 1984. Dr. Feinberg received a Bachelor of Science in Biology from the State University of New York, Binghamton and a Doctor of Medicine from State University of New York Downstate Medical Center in Brooklyn, New York. Dr. Feinberg completed a residency in Anesthesiology at University of Pennsylvania School of Medicine. He also received a Juris Doctorate degree from the Washington University School of Law, St. Louis, Missouri.


James A. McNulty, CPA, Chief Financial Officer, Treasurer, Secretary

James A. McNulty has been our Chief Financial Officer and Treasurer since 2014, and Secretary since 2017. He currently serves as Chief Executive Officer of MyMD Pharmaceuticals, Inc., as well as Manager and CFO of Hopkins Capital Group, an affiliation of limited liability companies which engage in venture activities primarily in development of pharmaceuticals. He served as Chief Financial Officer of Repurposed Therapeutics, Inc. and served as Secretary/Chief Compliance Officer for Hedgepath Pharmaceuticals, Inc. (OTC: HPPI) from 2013 through 2017, and since 2016 is a Director of CV Sciences, Inc. (  Mr. McNulty was Chief Financial Officer of Biodelivery Sciences International, Inc. (NASDAQ: BDSI) from 2000 until his retirement from BDSI in 2014. Mr. McNulty has performed accounting and consulting services, including expert testimony as a Certified Public Accountant since 1975. In 1976 he co-founded Pender McNulty & Newkirk, which became one of Florida's largest regional CPA firms, and was a founder/principal in two other CPA firms. He served as CFO of Star Scientific, Inc. and as CFO/COO of American Prescription Providers, Inc. and other affiliated companies. He is a published co-author (with Pat Summerall) of Business Golf, the Art of Building Relationships on the Links. Mr. McNulty is a graduate of University of South Florida, a licensed Certified Public Accountant, and is a member of the American and Florida Institutes of CPA's. He served several years as a board member of the Tampa Bay chapter of Financial Executives International. He is a board member of privately held Quantum Technology Sciences, Inc. (

Dr. David R. Helton, Chief Scientific Officer


David R. Helton has been our Chief Scientific Officer since 2014. Dr. Helton has over 40 years’ experience in the research and development of traditional pharmaceutical and biotechnology-derived products, with a diverse research and development background including drug discovery, behavioral/safety pharmacology, toxicology, regulatory affairs, medical affairs, project management, marketing, and business development. He has authored or co-authored over 120 scientific papers and is an inventor on over 50 patents worldwide. David’s academic research focused on mechanisms and treatment of emesis, in collaboration with NASA. David began his industry career with Eli Lilly and Company ("Lilly"), and subsequently expanded on the sound pre-clinical drug-development knowledge gained at Lilly by gaining clinical and regulatory experience at Quintiles, Inc. (Head, Medical Affairs) and B. Braun Medical, Inc. (Director of Pharmacology and Corporate Toxicologist). Following two years as the Executive Director of Research in an emerging biotech company, Neotherapeutics, David founded and established Cenomed, Inc., a pharmaceutical discovery and development company with a focus on psychiatric and neurologic disease. Since its inception in 2002, Cenomed, Inc., has partnered with B. Braun Medical, Inc. (Biological Test Center, 2004); with Abraxis Bioscience, Inc., in 2007 to form the joint venture Cenomed BioSciences LLC (acquired by Celgene in 2009); and with Keystone Pharmaceuticals to form the joint venture Cenomed Research LLC, a company focused on the needs of the Warfighter and Veteran. In 2010, after licensing technology from Cenomed, David co-founded Epiomed Therapeutics, Inc., and partnered with NDI Capital to develop compounds for emesis (nausea and vomiting) and performance sustainment.  Epiomed was acquired by Repurposed Therapeutics, Inc., in 2014.  Notable grants and research collaborations include joint projects with the US Navy, NASA, the Defense Threat Reduction Agency, Wright-Patterson Air Force Base, DARPA, USAMRICD, Wright State University, Mississippi State University, and Johns Hopkins University Applied Physics Laboratory. Most recently, David was a Distinguished Visitor aboard the Carrier USS JOHN C. STENNIS, where he was afforded a very rare, first-hand look at life aboard an aircraft carrier. After becoming a “Tailhooker” (trapping on and launching off the carrier), he witnessed the pride and professionalism displayed by the young men and women who serve our country. David conducted his undergraduate and graduate work at Wright State University (Dayton, Ohio) and Purdue University (Indianapolis, Indiana), graduating magna cum laude, and was awarded the Distinguished Senior Scholarship, Sigma Xi Scholarship, and two Sigma Xi “Excellence in Science” Research Awards.

Dr. Niraj Vasisht, PhD, Director
Niraj Vasisht, PhD has been a Director of our company since 2017. Dr. Vasisht is the President and CEO of Avior Inc.  Prior to Avior, he was the Chief Technology Officer at Bio Delivery Sciences (Nasdaq: BDSI) where he responsible for building the company’s pipeline, selecting drug candidates, leading CMC and Quality Operations, supporting DMPK and clinical development, and seeking drug approval. During his tenure, he co-led the development efforts through approval of three US commercial products – BELBUCA®, BUNAVAIL®, and ONSOLIS®, and two ex-US approval – Breakyl® in the EU and Painkyl® in Taiwan. Prior to BDSI, Dr. Vasisht served as the Director of Nanomaterials and Pharmaceutical Development at Southwest Research Institute where he operated a small business unit and led a team of prolific researchers in product conceptualization, product development, engineering scale up and commercial manufacturing across pharmaceutical, consumer health, and nutraceutical industry. There, he contributed in the early stage development of nutraceuticals (meg-3®), OTC (Citracal-D®) and pharmaceutical Rx products (Probuphine®, INSCOP). He is the inventor of 17 patents, numerous presentations and publications. He received a Bachelors’ from the Indian Institute of Technology at Kanpur, India, a Masters’ from the University of New Hampshire, and a PhD in Chemical Engineering from Rensselaer Polytechnic Institute.
John J. "Jack" Shea, Director

John J. Shea has been a member of our board of directors since June 23, 2015, and was a member of the BioDelivery Sciences International, Inc. board of directors from March 2002 through December 2014, and served as Chairman of the Nominating and Corporate Governance Committee of their board of directors. He is currently the head of his own firm J. Shea Inc. and has previously served as a Quality Systems Adviser with Quintiles, a private consulting firm. Mr. Shea has also served in the capacity of Director of Quality Assurance and was responsible for the implementation of quality assurance procedures in a number of public companies. From 1987-1989, he served as Director of Quality Assurance at NeoRx Corporation. Mr. Shea was also the Director of Corporate Quality Assurance at Hexcel Corporation from 1980-1987. Mr. Shea has also served as the quality assurance person for other companies including, Teledyne Relays, Ortho Diagnostics, Inc. and Bio Reagents & Diagnostics, Inc. He is a member of the (North Carolina) Dare County Airport Authority and Audit Committee. Mr. Shea is qualified to serve on our board of directors because of his extensive business experience in the pharmaceutical industry. Mr. Shea earned a B.S. in Chemistry at Bethany College.

© 2019 Repurposed Therapeutics, Inc.